Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum

Molecular Brain Research

Volumn 47, Issue 1-2, 1997, Pages 331-338

  Healy, Daniel J ^a   Meador Woodruff, James H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antipsychotics; Glutamate; Hybridization, in situ; Nucleus accumbens; Schizophrenia

Indexed keywords

AMPA RECEPTOR; CLOZAPINE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; KAINIC ACID RECEPTOR; MESSENGER RNA; NEUROLEPTIC AGENT; NEUROTRANSMITTER; RECEPTOR SUBUNIT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; IN SITU HYBRIDIZATION; LIMBIC CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CEREBRAL CORTEX; CLOZAPINE; CORPUS STRIATUM; HALOPERIDOL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RNA, MESSENGER;

EID: 0030968802     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00064-8     Document Type: Article

References (29)

1. B. Angrist, E. Peselow, M. Rubinstein, J. Corwin, J. Rotrosen, Partial improvement in negative schizophrenic symptoms after amphetamine, Psychopharmacology 78 (1982) 128-130.
2. N. Burnashev, H. Monyer, P.H. Seeburg, B. Sakmann, Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit, Neuron 8 (1992) 189-198.
3. M. Carlsson, A. Carlsson, Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease, Trends Neurosci. 13 (1990) 272-276.
4. M. Carlsson, A. Carlsson, Schizophrenia: a subcortical neurotransmitter imbalance syndrome?, Schizophrenia Bull. 16 (1990) 425-432.
5. I. Creese, I.R. Burt, S.H. Snyder, Dopamine receptor binding predicts clincial and pharmacological potencies of antischizophrenic drugs, Science 192 (1976) 481-483.
6. D.A. Daly, B. Moghaddam, Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats, Neurosci. Lett. 152 (1993) 61-64.
7. K.L. Davis, R.S. Kahn, G. Ko, M. Davidson, Dopamine in schizophrenia: a review and reconceptualization, Am. J. Psychiatry 148 (1991) 1474-1486.
8. J.F. Deakin, P. Slater, M.D. Simpson, A.C. Gilchrist, W.J. Skan, M.C. Royston, G.P. Reynolds, A.J. Cross, Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia, J. Neurochem. 52 (1989) 1781-1786.
9. S.L. Eastwood, P. Story, P.W.J. Burnet, P. Heath, P.J. Harrison, Differential changes in glutamate receptor subunit messenger RNAs in rat brain after haloperidol treatment, J. Psychopharmacol. 8 (1994) 196-203.
10. L.W. Fitzgerald, A.Y. Deutch, G. Gasic, S.F. Heinemann, E.J. Nestler, Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs, J. Neurosci. 15 (1995) 2453-2461.
11. P.J. Harrison, D. McLaughlin, R.W. Kerwin, Decreased hippocampal expression of a glutamate receptor gen in schizophrenia, Lancet 337 (1991) 450-452.
12. D.J. Healy, J.H. Meador-Woodruff, Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems, Brain Res. 708 (1996) 38-44.
13. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition, Science 252 (1991) 851-853.
14. M. Hollmann, S. Heinemann, Cloned glutamate receptors, Annu. Rev. Neurosci. 17 (1994) 31-108.
15. M. Ishimaru, A. Kurumaji, M. Toru, Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis, Biol. Psychiatry 35 (1994) 84-95.
16. D.S. Janowsky, K. El-Yousef, J.M. Davis, H.J. Sekerke, Provocation of schizophrenic symptoms by intravenous administration of methylphenidate, Arch. Gen. Psychiatry 28 (1973) 185-191.
17. R. Kerwin, S. Patel, B. Meldrum, Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem, Neuroscience 39 (1990) 25-32.
18. J.A. Lieberman, J.M. Kane, J. Alvir, Provocative tests with psychostimulant drugs in schizophrenia, Psychopharmacology 91 (1987) 415-433.
19. L. McCoy, E.K. Richfield, Effects of typical and atypical antipsychotics on AMPA site binding, Biol. Psychiatry 39 (1996) 586.
20. J.H. Meador-Woodruff, R.E. King, S.P. Damask, K.A. Bovenkerk, Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine, Mol. Psychiatry 1 (1996) 41-53.
21. 3H]kainic acid binding in the prefrontal cortex in schizophrenia, Neurosci. Lett. 40 (1983) 245-250.
22. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, New York, NY, 1986.
23. R.E. See, M. Chapman, Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats, Eur. J. Pharmacol. 263 (1994) 269-276.
24. P. Seeman, T. Lee, M. Chau-Wong, K. Wong, Antipsychotic drug doses and neuroleptic/dopamine receptors, Nature 261 (1976) 717-719.
25. S. Snyder, The dopamine hypothesis in schizophrenia: focus on the dopamine receptor, Am. J. Psychiatry 133 (1976) 197-202.
26. D.P. van Kammen, J.J. Boronow, Dextro-amphetamine diminishes negative symptoms in schizophrenia, Int. Clin. Psychopharmacol. 3 (1988) 111-121.
27. D.R. Weinberger, K.F. Berman, B.P. Illowsky, Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III: a new cohort and evidence for a monoaminergic mechanism, Arch. Gen. Psychiatry 45 (1988) 609-615.
28. B.K. Yamamoto, M. Cooperman, Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations, J. Neurosci. 14 (1994) 4159-4166.
29. B.K. Yamamoto, E.A. Pehek, H.Y. Meltzer, Brain region effects of clozapine on amino acid and monoamine transmission, J. Clin. Psychiatry 55 ([9, Suppl. B]) (1994) 8-14.